In the News | Friends of Cancer Research

You are here

In the News

Washington Post- Local, State Agencies Lack Resources to Ensure Food Safety

Congress Must Fix System, Report Says, By Lyndsey Layton, Local and state health officials trying to prevent food illness outbreaks are stymied by scarce resources,

 weak leadership from the federal government and bureaucratic barriers, according to a new study public health experts released yesterday.

Comparative effectiveness research panel holds first session

WASHINGTON, D.C. — A newly formed federal council held its first meeting here today, a listening session in which members were told by various interest groups how the government should best spend $1.1 billion

 to advance research that compares the effectiveness of various medical treatments.

Wall Street Jounral- Push to Compare Treatments Worries Drug, Device Makers Article

By Jane hang, WASHINGTON -- Federal health-care agencies are getting $1.1 billion in economic-stimulus funds

 for research comparing the effectiveness of various treatments. But  drug and medical-device makers, along with some members of Congress, say they are worried the findings will be used to limit patients' options.

Washington Post- Obama Makes Health Reform Office Official

By Ceci Connolly, One month after its director began work, President Obama made it official today: There's a new White House Office of Health Reform.

Wall Street Journal- Torti’s Farewell Memo to FDA Staff: ‘Take the FDA Back’

By Sarah Rubenstein Not long after sending out a memo warning FDA staff about leaking confidential information — and then seeing the memo get leaked —

Frank Torti sent out a farewell message to the staff on Friday. That, too, was leaked, and it offered some interesting words on the state of the agency:

FDA Week- Sentinel Could Help Choose Comparative Effectiveness Projects

 By John Wilkerson, FDA’s Sentinel Initiative and other large data networks should be used to choose comparative effectiveness research projects, a cancer research advocacy groups says.

 Many believe the government’s designs on comparative effectiveness are at odds with FDA’s emphasis on personalized medicine, so the Friends of Cancer Research is looking into how the two approaches could inform each other and not be seen as opposites. 

Houston Chronicle- Now’s time to reinvigorate country’s War on Cancer

By U.S. SENS. EDWARD M. KENNEDY and KAY BAILEY HUTCHISON

Cancer is a relentless disease. It doesn’t discriminate between men and women, wealthy or poor, the elderly or the young.

Washington Post- After Cancer, Lawmaker Urges Tests

 By Richard Leiby, She didn't cry on "Good Morning America." She didn't cry when she talked to the local press. But yesterday, surrounded by a sisterhood of other breast cancer survivors, Rep. Debbie Wasserman Schultz stood looking so vulnerable and human

 -- so unlike a typical member of Congress -- at a lectern in a small Capitol dining room, and broke down repeatedly.

Dow Jones- Roche's Herceptin Extends Life In Aggressive Stomach Cancer

By Hans Schoemaker

ZURICH -(Dow Jones)- Drugmaker Roche Holding AG

(ROG.VX) said Wednesday that new data shows its breast cancer drug Herceptin also shows benefits when used to treat aggressive stomach cancer.   The results, from ToGA, a large international Phase III trial, show that Herceptin significantly prolongs the lives of patients with HER2-positive advanced stomach cancer.

"This is definitely good news," said Karl-Heinz Koch, an analyst at Helvea, who rates the stock at buy.

Comparison Shopping for Medicine

Obama's Stimulus Package Funds Research on Cutting Costs By Ceci Connolly

What's best for insomnia -- Lunesta, at about $6 a pill, or Zolpidem, at $2?

Should a man with prostate cancer choose radiation, surgery or "watchful waiting"?

Is it better to operate on a bad knee or get an injection of the joint fluid known as Visco.

To help doctors and patients decide, President Obama has dedicated $1.1 billion in the economic stimulus package for federal agencies to oversee studies on the merits of competing medical treatments.

Pages